Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Клики: 35
ID: 281457
2022
Метрики качества и эффективности статьи
Общее качество
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Вовлечённость читателей
Star Article
10.2
/100
35 просмотры
10 читатели
Оценка качества ИИ
Не проанализировано
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Аннотация
With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy.
| Ссылочный ключ |
yang2022recent
Используйте этот ключ для автоцитирования в рукописи при использовании
SciMatic Manuscript Manager или Thesis Manager
|
|---|---|
| Авторы | Ling Yang; Qiang Ning; Shengsong Tang |
| Журнал | Journal of Immunological Research |
| Год | 2022 |
| DOI |
10.1155/2022/8052212
|
| URL | |
| Ключевые слова | Ключевые слова не найдены |
Цитирования
Цитирования не найдены. Чтобы добавить цитирование, свяжитесь с администратором по адресу info@scimatic.org
Комментарии
Комментариев пока нет. Будьте первым, кто прокомментирует эту статью.